Blood products

The Blood Center of New Orleans Cooperates With Biolog-id to Enhance Visibility, Availability, and Traceability of Life-saving Blood Components

Retrieved on: 
Monday, June 21, 2021
Technology, Medical devices, Other Technology, Software, Other Health, Biotechnology, Hardware, General Health, Health, Data management, Blood, Branches of biology, Transfusion medicine, Anatomy, Hematology, Blood products, Platelet, Transfusion, Iranian Blood Transfusion Organization

We are firm believers in leveraging technology to improve the efficiency, quality, and safety of the blood supply, said Billy Weales, President & CEO at The Blood Center.

Key Points: 
  • We are firm believers in leveraging technology to improve the efficiency, quality, and safety of the blood supply, said Billy Weales, President & CEO at The Blood Center.
  • Our cooperation with biolog-id allows us to achieve these goals with two of our most critical blood components platelets and rare red blood cells.
  • Founded in 1960, The Blood Center is the primary supplier of blood, blood components, and plasma derivatives to local hospitals throughout South Louisiana and parts of the Mississippi Gulf Coast.
  • The Blood Center supplies over 50 hospitals and numerous outpatient transfusion facilities in Southeast Louisiana and Southern Mississippi.

Organicell Launches Autologous Blood Derived Platform PPX™ – Patient Pure X™

Retrieved on: 
Wednesday, June 9, 2021
Research, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Branches of biology, Blood, Transfusion medicine, Blood products, Platelet, Regenerative medicine, Peripheral blood mononuclear cell

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company launched a service platform for their first autologous product called Patient Pure XTM (PPXTM).

Key Points: 
  • Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company launched a service platform for their first autologous product called Patient Pure XTM (PPXTM).
  • PPXTM is a non-manipulated biologic containing the nanoparticle fraction from a patients own peripheral blood.
  • Similar to the origin of growth factors present in platelet rich plasma (PRP), nanoparticles derived from platelets and peripheral blood mononuclear cells may carry signaling molecules to deliver a regenerative effect.
  • We are very excited to launch this novel service platform to widen the opportunities of regenerative medicine for physicians and patients, said Albert Mitrani, CEO of Organicell.

India Blood Plasma Products Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 2, 2021
Pharmaceutical, Health, Cardiology, Anatomy, Body fluids, Branches of biology, Transfusion medicine, Blood products, Hematology, Blood, Blood plasma, Plasma, Blood plasma fractionation, Plasmapheresis

The "Blood Plasma Products Market in India 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Plasma Products Market in India 2021" report has been added to ResearchAndMarkets.com's offering.
  • Plasma is a major component of the blood that plays an essential role in regulating bodily functions.
  • The blood plasma products market has been experiencing steady growth over the past few years.
  • Plasma derivative-based therapy is a cost-effective solution to develop human plasma products such as antibodies and proteins in the long run.

Global Platelet Rich Plasma (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Pharmaceutical, Health, Blood, Branches of biology, Transfusion medicine, Anatomy, Blood products, Platelet-rich plasma, Platelet, PRP, Blood plasma, Compound annual growth rate

The "Platelet Rich Plasma (PRP) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Platelet Rich Plasma (PRP) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Pure Platelet Rich Plasma, one of the segments analyzed in the report, is projected to record a 10.4% CAGR and reach US$481.6 Million by the end of the analysis period.
  • After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Leukocyte Rich Platelet Rich Plasma segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
  • The U.S. Market is Estimated at $122.3 Million, While China is Forecast to Grow at 14.1% CAGR
    The Platelet Rich Plasma (PRP) market in the U.S. is estimated at US$122.3 Million in the year 2020.

Bimini Health Tech Receives CE Mark for Next Generation PRP System

Retrieved on: 
Wednesday, May 26, 2021
Branches of biology, Transfusion medicine, Blood products, Platelet-rich plasma, Platelet, Bimini

SOLANA BEACH, Calif., May 26, 2021 /PRNewswire/ --Bimini Health Tech, announced today it has expanded its portfolio of approved products with the achievement of the CE Mark for its next-generation blood separation system for Platelet Rich Plasma (PRP) preparation, the Healeon Duet.

Key Points: 
  • SOLANA BEACH, Calif., May 26, 2021 /PRNewswire/ --Bimini Health Tech, announced today it has expanded its portfolio of approved products with the achievement of the CE Mark for its next-generation blood separation system for Platelet Rich Plasma (PRP) preparation, the Healeon Duet.
  • "The Healeon Duet overcomes one of the most challenging parts of platelet preparation -- customizing concentration levels in controlled dosages for specific procedure types in a single platform," said Jeff Greiner, CCO of Bimini Health Tech.
  • Bimini Health Tech is a global leader in the medical aesthetics and regenerative market.
  • The Bimini Health Tech portfolio includes Healeon, Puregraft, Dermapose, and Kerastem.

ADMA Biologics Receives FDA Approval for Increased IVIG Production Scale

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Anatomy, Clinical medicine, Transfusion medicine, Blood products, Blood, Blood plasma, Hematology, Plasmapheresis, Adma

ADMA now has FDA approval to produce BIVIGAM\xc2\xae at an expanded capacity with the same high quality as the previous manufacturing scale, while using the same equipment, release testing assays, disposables and labor force.

Key Points: 
  • ADMA now has FDA approval to produce BIVIGAM\xc2\xae at an expanded capacity with the same high quality as the previous manufacturing scale, while using the same equipment, release testing assays, disposables and labor force.
  • The Company anticipates this will translate into meaningful gross margin improvement as production throughput flows through the standard 7 to 12-month manufacturing cycle for plasma-derived therapies.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.
  • Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products.

Honor Moms, Get Thanked When Giving Blood this May with Vitalant

Retrieved on: 
Wednesday, April 28, 2021
Blood, Branches of biology, Medical specialties, Transfusion medicine, Hematology, Blood products, Blood transfusion, Blood type, Blood donation, Platelet, Vitalant, Plateletpheresis

b'SCOTTSDALE,Ariz., April 28, 2021 /PRNewswire/ --Nonprofit blood services provider Vitalant urges all eligible donors to make an appointment to give blood, platelets or plasma this May in support of mothers and all patients relying on lifesaving blood transfusions.

Key Points: 
  • b'SCOTTSDALE,Ariz., April 28, 2021 /PRNewswire/ --Nonprofit blood services provider Vitalant urges all eligible donors to make an appointment to give blood, platelets or plasma this May in support of mothers and all patients relying on lifesaving blood transfusions.
  • There is an urgent need for donors to help new mothers experiencing childbirth complications, grandmothers battling cancer, sisters with chronic blood disorders, and other patients.
  • "Trauma and accident victims, cancer patients and those now undergoing previously postponed surgeries may all need blood.
  • Donors with all blood types are needed, especially type Othe most transfused blood type.

Nuo Therapeutics Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Transfusion medicine, Blood products, Platelet-rich plasma, Platelet, Chronic wound, Nuo, Centers for Medicare & Medicaid Services, Medicare, Wound

b'HOUSTON, April 20, 2021 /PRNewswire/ --Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4).

Key Points: 
  • b'HOUSTON, April 20, 2021 /PRNewswire/ --Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4).
  • On April 13, 2021, Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo (available at the URL at the bottom of this release) that Medicare will cover autologous platelet-rich plasma (PRP) for treatment of chronic non-healing diabetic wounds (DFUs) under section 1862(a)(1)(A) of the Social Security Act.
  • This final decision follows the favorable proposed decision memo which was published December 21, 2020 and followed by a thirty-day public comment period.
  • Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Greenberg Traurig Advises Tiancheng Investment Management in $370 Million Sale of 25 U.S.-Based Plasma Donation Centers from Bio Products Laboratory to Grifols

Retrieved on: 
Tuesday, March 30, 2021
Branches of biology, Clinical medicine, Anatomy, Blood products, Transfusion medicine, Greenberg Traurig, Grifols, Blood plasma, GT, Bio Products Laboratory, Plasmapheresis, BPL

As part of the $370 million transaction, Grifols' subsidiary, Biomat USA, acquired 25 U.S.-based plasma donation centers from BPL Plasma Inc., a subsidiary of Bio Products Laboratory Holdings Limited, a global supplier of high-quality plasma derived medicines headquartered in the United Kingdom and with plasma collection centers across the United States.

Key Points: 
  • As part of the $370 million transaction, Grifols' subsidiary, Biomat USA, acquired 25 U.S.-based plasma donation centers from BPL Plasma Inc., a subsidiary of Bio Products Laboratory Holdings Limited, a global supplier of high-quality plasma derived medicines headquartered in the United Kingdom and with plasma collection centers across the United States.
  • Elowe concentrates his practice on international mergers and acquisitions, joint ventures, strategic investments and alliances, licensing, and technology transactions.
  • About Greenberg Traurig's Life Sciences & Medical Technology Group: Greenberg Traurig's Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions.
  • About Greenberg Traurig, LLP: Greenberg Traurig, LLP (GT), has approximately 2200 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East.

San Antonio’s 120-gallon-plus blood donors encourage others to give

Retrieved on: 
Friday, March 19, 2021
Blood, Branches of biology, Transfusion medicine, Medical specialties, Hematology, Blood products, Blood donation, Platelet, Whole blood, Plateletpheresis, New Zealand Blood Service

Perkins, who first gave blood in 1950, is at 121 gallons just at the South Texas Blood & Tissue Center.

Key Points: 
  • Perkins, who first gave blood in 1950, is at 121 gallons just at the South Texas Blood & Tissue Center.
  • Platelet donors can give every two weeks, up to 24 times a year, and whole blood donors can give every 56 days.
  • His final assignment was at Fort Sam Houston in San Antonio, where he started donating at the bases blood center.
  • About the South Texas Blood & Tissue Center: The South Texas Blood & Tissue Center (STBTC) is a nonprofit community blood center that provides blood, plasma, platelets and other blood components to 100 hospitals in 48 South Texas counties.